Staphylococcus aureus enterotoxins are potent superantigens known for inducing strong T cell activation, which can lead to cytokine storms and significant immune responses. Recent advancements in T cell-based cancer immunotherapies, including CAR-T cell therapy and immune checkpoint inhibitors, highlight the potential role of modified superantigens as adjuvants to boost immune activation. This study proposes a modified version of Enterotoxin C (ENTC3), with targeted amino acid changes to reduce toxicity while retaining its immune-activating capabilities. By altering residues at positions 74, 145, and 149, T cell stimulation is anticipated to reduce by 30%, and emetic toxicity is expected to be eliminated. Additionally, as a foodborne toxin, Enterotoxin C’s stability under heat and digestion allows for potential oral administration, enhancing its applicability as an immune adjuvant with reduced invasiveness. Experimental work will involve expression, purification, and in vivo testing of the modified enterotoxin to evaluate T cell activation and safety, supporting its potential as an effective adjuvant in immunotherapy.